J Clin Outcomes Manage
Evaluation and management of newly diagnosed multipe myeloma
Abstract Objective: To discuss the diagnosis and management of newly diagnosed multiple myeloma (MM). Methods: Review of the literature and case presentation. Results: Treatment of MM has evolved over the past 20 years, with the development of immunomodulatory drugs (thalidomide, lenalidomide, and pomalidomide) and proteosome inhibitors (bortezomib and carfilzomib) resulting in improved outcomes. Epidemiologic studies from the Mayo Clinic and Sweden have shown dramatic survival gains in recent years due to these novel agents. The current treatment paradigm is divided into 3 phases: induction, consolidation, and maintenance. The approach to each phase of therapy is individualized based on the features of the myeloma, age, comorbidities, and personal preferences. Conclusion: Outcomes for patients with MM have improved significantly over the past 20 years due to several therapeutic advances. A major challenge remains to develop effective therapies for high-risk MM subsets that have not been substantially impacted by novel agents.
Clinical Review Article
Search the Turner White index to find abstracts of articles published in JCOM.